Evidence map›Paper›PMID 31179484›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2020

Cryptococcal Antigen Screening and Preemptive Treatment-How Can We Improve Survival?

Radha Rajasingham, David R Boulware

Abstract readComment
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Trial
  2. Article
  3. Review
  4. Review
  5. Cryptococcal meningitis.Nature reviews. Disease primers · 2023
    Review
  6. Preemptive Therapy in Cryptococcosis Adjusted for Outcomes.Journal of fungi (Basel, Switzerland) · 2023
    Article
  7. Review
  8. Recent Trends in the Epidemiology of Fungal Infections.Infectious disease clinics of North America · 2021
    Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Radha RajasinghamDivision of Infectious Diseases and International Medicine, Department of Medicine, University of Minnesota, Minneapolis.
David R BoulwareDivision of Infectious Diseases and International Medicine, Department of Medicine, University of Minnesota, Minneapolis.

Funding

Operational Research for Cryptococcal Antigen Screening (ORCAS) of HIV PatientsU01AI125003 · NIAID · UNIVERSITY OF MINNESOTA · PI BOULWARE, DAVID R, MEYA, DAVID BISAGAYA · 2016 to 2020
$3.4M
Phased Implementation of a Public Health Programme: Cryptococcal Screening and Treatment in South AfricaR01AI118511 · NIAID · UNIVERSITY OF MINNESOTA · PI BOULWARE, DAVID R, GOVENDER, NELESH PREMAPRAGASAN · 2016 to 2020
$2.9M
Evaluation of CRAG screening with enhanced antifungal therapy for asymptomatic CRAG-positive personsK23AI138851 · NIAID · UNIVERSITY OF MINNESOTA · PI RAJASINGHAM, RADHA · 2018 to 2022
$954k
NIAID NIH HHS K23 AI138851NIAID NIH HHS R01 AI118511NIAID NIH HHS U01 AI125003
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

CryptococcusFluconazoleAntigens, FungalHumansAntigens, FungalFluconazoleAIDScryptococcal meningitisCryptococcusHIVscreening

Identifiers

PMID31179484
PMCPMC7145997

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.